Literature DB >> 469447

Congenital complete heart block and long Q-T syndrome requiring ventricular pacing for control of refractory ventricular tachycardia and fibrillation.

J A Gascho, R Schieken.   

Abstract

A three-year-old girl with congenital complete heart block presented with repeated bouts of ventricular tachycardia and ventricular fibrillation. The ECG was remarkable for both complete heart block and a long Q-T interval, when corrected for rate. The Q-T interval was longer than the Q-T interval of children with congenital complete heart block and of children without heart disease. Overdrive ventricular pacing was necessary to control the arrhythmias. A prolonged Q-T interval in patients with complete heart block, even in the presence of a normal QRS duration, may predispose the patient to sudden death. Permanent pacing can suppress these arrhythmias by overdriving.

Entities:  

Mesh:

Year:  1979        PMID: 469447     DOI: 10.1016/s0022-0736(79)80069-2

Source DB:  PubMed          Journal:  J Electrocardiol        ISSN: 0022-0736            Impact factor:   1.438


  5 in total

1.  Stokes-Adams attack.

Authors:  G Nikolic
Journal:  Pediatr Cardiol       Date:  1989       Impact factor: 1.655

2.  Congenital complete atrioventricular block associated with QT prolongation: Description of a patient with an unusual outcome.

Authors:  Alberto Mendoza; Silvia Belda; Rafael Salguero; Miguel Angel Granados
Journal:  Pediatr Cardiol       Date:  2010-05-22       Impact factor: 1.655

Review 3.  QT-interval prolonging drugs: mechanisms and clinical relevance of their arrhythmogenic hazards.

Authors:  M Zehender; S Hohnloser; H Just
Journal:  Cardiovasc Drugs Ther       Date:  1991-04       Impact factor: 3.727

Review 4.  Drug-induced torsade de pointes. Incidence, management and prevention.

Authors:  T S Faber; M Zehender; H Just
Journal:  Drug Saf       Date:  1994-12       Impact factor: 5.606

Review 5.  Drug-induced cardiac arrhythmias: incidence, prevention and management.

Authors:  J C Doig
Journal:  Drug Saf       Date:  1997-10       Impact factor: 5.228

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.